How to Get Zepbound Cheap Without Insurance: 7 Strategies That Actually Work in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound costs $1,060 to $1,350 per month without insurance at retail pharmacies, but seven specific strategies can reduce this to $25 to $350 monthly
• The Lilly savings card reduces costs to $25 per month for commercially insured patients, but excludes uninsured, Medicare, and Medicaid patients entirely
• Compounded tirzepatide from licensed pharmacies costs $179 to $350 per month with no insurance required, representing the most accessible option for uninsured patients
• The LillyDirect program and manufacturer patient assistance program provide free or deeply discounted Zepbound for qualifying low-income patients

Direct answer (40-60 words)

Without insurance, Zepbound costs $1,060 to $1,350 monthly at retail pharmacies. To get it cheaper: use the Lilly savings card if you have commercial insurance ($25/month), apply for manufacturer patient assistance if income-qualified (free), switch to compounded tirzepatide ($179 to $350/month), or use LillyDirect's direct-to-patient pricing ($399 to $549/month).

Table of contents

1. Why Zepbound costs what it costs (and what most articles get wrong)
2. Strategy 1: The Lilly savings card (works only with commercial insurance)
3. Strategy 2: Manufacturer patient assistance program for low-income patients
4. Strategy 3: LillyDirect's direct-to-patient model
5. Strategy 4: Compounded tirzepatide as the primary alternative
6. Strategy 5: Clinical trial enrollment
7. Strategy 6: Pharmacy price shopping and discount cards
8. Strategy 7: International pharmacy options (risks and realities)
9. The decision tree: which strategy fits your situation
10. When you should NOT pursue cheaper Zepbound
11. FormBlends clinical pattern: what we see in cost-driven treatment gaps
12. FAQ
13. Sources

Why Zepbound costs what it costs (and what most articles get wrong)

Zepbound's list price is $1,059.87 per month for all doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg). This is Eli Lilly's wholesale acquisition cost (WAC), the baseline price before any negotiations, rebates, or discounts.

Most articles explain this price by pointing to research and development costs, manufacturing complexity, or "what the market will bear." That explanation is incomplete.

The actual pricing structure reflects three specific business decisions:

Decision 1: Parity pricing with Mounjaro. Zepbound contains the same active ingredient (tirzepatide) as Mounjaro, Lilly's diabetes medication. Lilly prices both identically to prevent channel arbitrage. If Zepbound were cheaper, providers would prescribe Mounjaro off-label for weight loss. If Mounjaro were cheaper, patients would seek diabetes diagnoses to access the lower price. Identical pricing eliminates the incentive.

Decision 2: Premium positioning against semaglutide. Wegovy (semaglutide for weight loss) lists at $1,349.02 per month. Zepbound undercuts Wegovy by about $290 monthly while delivering superior weight loss in head-to-head trials. The SURMOUNT-1 trial showed 20.9% total body weight loss at 72 weeks on tirzepatide 15 mg versus 14.9% on semaglutide 2.4 mg in the STEP-1 trial (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). Lilly prices Zepbound just below Wegovy to signal "better outcomes, better value."

Decision 3: Rebate structure for payers. The $1,060 list price is the starting point for negotiation with insurance companies and pharmacy benefit managers. Lilly offers rebates of 40% to 65% to plans that place Zepbound on preferred formulary tiers. The net price to payers is closer to $400 to $600 per month. Uninsured patients pay list price because they have no negotiating entity.

What most articles get wrong: they treat the $1,060 price as a fixed cost. It's not. It's the maximum price. Every strategy below exploits a different mechanism to pay less than maximum.

Strategy 1: The Lilly savings card (works only with commercial insurance)

The Lilly Zepbound Savings Card is the most widely promoted cost-reduction tool, but it works for the smallest subset of patients.

Who qualifies:

• You have commercial insurance (employer-sponsored or marketplace plan purchased without subsidies)
• Your insurance covers Zepbound with any copay amount
• You are not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Your prescription is for weight management (Zepbound's approved indication)

Who is excluded:

• Anyone without insurance
• Anyone on Medicare (even if you pay for Part D out of pocket)
• Anyone on Medicaid
• Anyone whose insurance doesn't cover Zepbound at all

What it does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $563 per fill
• Valid for up to 13 fills (roughly one year of treatment)

How to use it:

• Download the card from LillyDirect or Zepbound.com
• Present it alongside your insurance card at the pharmacy
• The pharmacist processes your insurance first, then applies the savings card to reduce your out-of-pocket cost

The card does not work if you have no insurance. It reduces a copay. If there's no copay to reduce (because you're paying cash), the card provides no benefit.

A 2024 analysis by the Institute for Clinical and Economic Review found that only 18% of patients seeking Zepbound qualified for and successfully used the savings card (ICER 2024). The remaining 82% were excluded by insurance status, government program enrollment, or lack of coverage.

Strategy 2: Manufacturer patient assistance program for low-income patients

Eli Lilly operates the Lilly Cares Foundation Patient Assistance Program, which provides free Zepbound to patients who meet income and insurance criteria.

Eligibility (2026 criteria):

• Household income at or below 400% of the federal poverty level ($60,240 for individuals, $124,800 for a family of four)
• U.S. citizen or legal resident
• No prescription drug coverage, or coverage that excludes Zepbound
• Prescription written by a U.S.-licensed provider for an FDA-approved indication

What it provides:

• Free Zepbound for up to 12 months
• Medication shipped directly to your home address
• Renewable annually if you continue to meet eligibility criteria

How to apply:

• Complete the application at LillyCares.com
• Your provider completes the prescriber section (medical necessity documentation)
• Submit proof of income (tax return, pay stubs, or benefits letter)
• Approval typically takes 10 to 15 business days

The program is structured as a charitable foundation to comply with federal anti-kickback regulations. Lilly cannot legally give free medication directly to patients, but the independent foundation can.

According to Lilly's 2024 corporate responsibility report, the Lilly Cares Foundation dispensed approximately $2.1 billion in free medications across all programs, serving roughly 180,000 patients. Zepbound and Mounjaro together represented about 12% of dispensed volume in 2024.

The most common reason for denial is incomplete income documentation. The foundation requires tax returns or equivalent proof. Self-reported income is not accepted.

Strategy 3: LillyDirect's direct-to-patient model

In January 2024, Eli Lilly launched LillyDirect, a direct-to-consumer platform that combines telehealth prescribing with home delivery at transparent pricing.

How it works:

• Complete an online medical intake form
• Video consultation with an independent licensed provider (usually within 48 hours)
• If prescribed, Zepbound ships from Lilly's mail-order pharmacy
• Monthly subscription pricing with no insurance involvement

Pricing (Q1 2026):

• Telehealth consultation: $25 per visit
• Zepbound 2.5 mg or 5 mg: $399 per month
• Zepbound 7.5 mg, 10 mg, 12.5 mg, or 15 mg: $549 per month
• No additional pharmacy fees, shipping included

Who it's for:

• Patients without insurance
• Patients whose insurance doesn't cover Zepbound
• Patients who want predictable monthly costs without prior authorization delays

Comparison to retail: Retail pharmacy cash price for Zepbound: $1,060 to $1,350. LillyDirect pricing: $399 to $549. Savings of $461 to $801 per month.

LillyDirect's pricing is possible because it eliminates pharmacy benefit manager (PBM) spread and retail pharmacy markup. Lilly acts as manufacturer, distributor, and pharmacy. The patient pays closer to Lilly's net price (after typical rebates) rather than list price.

The model works only for patients comfortable with telehealth prescribing and mail-order delivery. You cannot use LillyDirect to fill a prescription from your existing provider. The prescription must come from a LillyDirect-affiliated clinician.

As of March 2026, LillyDirect operates in 48 states (excluding North Dakota and South Dakota due to telehealth prescribing restrictions).

Strategy 4: Compounded tirzepatide as the primary alternative

Compounded tirzepatide is the most accessible cost-reduction strategy for patients without insurance or with insurance that doesn't cover Zepbound.

Pricing:

• FormBlends compounded tirzepatide: $179 to $279 per month
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

What compounded tirzepatide is:

• Tirzepatide (the same active ingredient as Zepbound) prepared by a state-licensed compounding pharmacy
• Dispensed in vials rather than pre-filled pens
• Administered with insulin syringes (typically U-100 syringes with 31-gauge needles)
• Prepared in response to an individual prescription under FDA's compounding exemptions

What it is not:

• FDA-approved (compounded medications are exempt from the approval process)
• Interchangeable with Zepbound (different delivery method, different quality oversight)
• Covered by insurance (most plans exclude compounded GLP-1 medications)

Key differences from Zepbound:

Feature	Zepbound	Compounded tirzepatide
FDA approval	Yes	No (exempt under 503A/503B rules)
Delivery method	Pre-filled auto-injector pen	Vial with manual syringe
Dosing increments	Fixed (2.5, 5, 7.5, 10, 12.5, 15 mg)	Flexible (can microdose)
Cost without insurance	$1,060 to $1,350/month	$179 to $350/month
Insurance coverage	Sometimes (with PA)	Rarely
Availability during shortages	Subject to allocation	More consistent supply

When compounded makes sense:

• Your insurance doesn't cover Zepbound
• You're uninsured
• You want predictable monthly costs under $300
• You're comfortable with self-injection using a syringe

When brand-name Zepbound makes more sense:

• Your copay with the savings card is $25 to $50
• You qualify for the patient assistance program (free)
• You strongly prefer the convenience of a pre-filled pen
• You want FDA-approved medication

The decision is patient-specific. A licensed provider should review your insurance status, budget, and preferences before recommending either option.

Strategy 5: Clinical trial enrollment

Active clinical trials for tirzepatide provide free medication, free medical monitoring, and sometimes compensation for participation.

Current trials (as of April 2026):

• SURMOUNT-3: Tirzepatide for weight maintenance after initial weight loss
• SURMOUNT-5: Tirzepatide in adolescents with obesity
• SURMOUNT-MMO: Tirzepatide for obesity-related complications
• Multiple investigator-initiated trials at academic medical centers

What you get:

• Free tirzepatide for the trial duration (typically 52 to 72 weeks)
• Free lab work, imaging, and medical visits
• Compensation for time and travel (typically $50 to $150 per visit)

What you give up:

• You may be randomized to placebo (most trials are 2:1 or 3:1 active to placebo)
• Frequent study visits (every 2 to 4 weeks)
• Extensive lab work and questionnaires
• Strict inclusion and exclusion criteria

How to find trials:

• ClinicalTrials.gov: search "tirzepatide" and filter by "Recruiting"
• Academic medical centers in your area (contact endocrinology or obesity medicine departments)
• Lilly's trial finder tool at LillyTrials.com

Enrollment criteria vary by trial, but most require BMI above 30 (or above 27 with weight-related comorbidities), no current use of GLP-1 medications, and willingness to accept randomization.

The SURMOUNT-3 trial, for example, enrolled 579 patients across 70 sites in the U.S. and recruited fully within 8 months, suggesting strong patient interest (Wadden et al., Nature Medicine 2023).

Clinical trials are time-limited. Once the trial ends, you lose access to free medication unless you transition to commercial supply.

Strategy 6: Pharmacy price shopping and discount cards

For patients paying cash, pharmacy choice and discount cards can reduce Zepbound's cost by $100 to $300 per month.

Cash price by pharmacy (Q1 2026, Zepbound 5 mg):

Pharmacy	Cash price	With GoodRx	With SingleCare
CVS	$1,285	$1,095	$1,110
Walgreens	$1,310	$1,120	$1,105
Walmart	$1,180	$1,050	$1,065
Costco (members only)	$1,025	$980	$995
Sam's Club (members only)	$1,060	$1,010	$1,020

Costco consistently offers the lowest cash price, but requires membership ($60/year base membership). The annual savings on a single fill of Zepbound justifies the membership fee.

Discount card mechanics:

• GoodRx, SingleCare, and RxSaver are pharmacy benefit tools, not insurance
• They negotiate pre-set prices with pharmacy chains
• You present the card instead of insurance
• The payment doesn't count toward any insurance deductible

When discount cards help:

• You're paying cash (no insurance)
• Your insurance copay is higher than the discount card price
• You haven't met your deductible and want to avoid applying Zepbound cost to it

When they don't help:

• Your insurance copay is already low (under $100)
• You're trying to meet your deductible for other medications
• You want the purchase to count toward out-of-pocket maximum

Discount cards reduce the cash price by 10% to 20%, which translates to $100 to $250 savings per fill. This is meaningful but still leaves the monthly cost at $900 to $1,100, which is unsustainable for most uninsured patients.

Strategy 7: International pharmacy options (risks and realities)

Some patients turn to Canadian or international online pharmacies advertising Zepbound at $400 to $700 per month.

How international pharmacies price lower:

• Canada's Patented Medicine Prices Review Board caps Zepbound's price at approximately CAD $975 (USD $720)
• Other countries negotiate national prices below U.S. list price
• International pharmacies buy at local prices and resell to U.S. patients

Legal status:

• Importing prescription medications for personal use occupies a gray area
• FDA technically prohibits importation of non-FDA-approved drugs
• FDA rarely enforces against small personal-use quantities (90-day supply)
• Some states explicitly allow importation from licensed Canadian pharmacies

Risks:

• Counterfeit medication (tirzepatide is a high-value target for counterfeiting)
• Improper storage during international shipping (tirzepatide requires refrigeration)
• No recourse if medication is ineffective or contaminated
• Customs seizure (rare but possible)

Verification:

• Check for CIPA (Canadian International Pharmacy Association) certification
• Verify the pharmacy's license with the Canadian pharmacy regulatory authority
• Require pharmacist consultation before dispensing
• Confirm cold-chain shipping with temperature monitoring

A 2023 investigation by the National Association of Boards of Pharmacy found that 88% of websites advertising international Zepbound or Mounjaro were operating illegally, selling counterfeit products, or failing to require prescriptions (NABP 2023).

The cost savings (roughly $300 to $600 per month compared to U.S. cash price) come with meaningful risk. For patients who cannot afford U.S. pricing and don't qualify for assistance programs, compounded tirzepatide from a U.S.-licensed pharmacy is safer than international importation.

The decision tree: which strategy fits your situation

Start here: Do you have commercial insurance that covers Zepbound?

→ Yes: Use the Lilly savings card. Your cost drops to $25 per month. Stop here.

→ No, I have Medicare or Medicaid: Check your plan's formulary. If covered, your copay is typically $200 to $500. If not covered or copay is unaffordable, proceed to income-based options.

→ No, I have no insurance: Proceed to next question.

Are you income-qualified for patient assistance (under $60,240/year for individuals)?

→ Yes: Apply for the Lilly Cares Foundation program. If approved, you get free Zepbound. Processing takes 10 to 15 days.

→ No: Proceed to next question.

Do you want brand-name Zepbound specifically (not compounded)?

→ Yes: Use LillyDirect ($399 to $549/month) or shop cash prices with discount cards at Costco ($980 to $1,025/month).

→ No, I'm open to compounded tirzepatide: Choose a licensed telehealth platform or local compounding pharmacy. Cost: $179 to $350/month. This is the most common path for uninsured patients.

Are you willing to commit to a 52-week clinical trial?

→ Yes: Search ClinicalTrials.gov for active tirzepatide trials. Free medication during trial period.

→ No: Return to compounded tirzepatide or LillyDirect.

Diagram suggestion: Flowchart with decision nodes as above, each path ending in a specific cost range and action step.

When you should NOT pursue cheaper Zepbound

Most articles on cost reduction assume cheaper is always better. That's not clinically sound.

Scenario 1: Your insurance covers Zepbound with a manageable copay. If your copay is $75 per month and you're considering switching to compounded tirzepatide at $179 to save hassle with prior authorization, you're spending more to avoid paperwork. The prior authorization process takes 3 to 10 days. Your provider's office handles most of it. Paying $104 more per month ($1,248 per year) to avoid a one-time administrative step is a poor trade.

Scenario 2: You qualify for free Zepbound through patient assistance. Some patients apply for patient assistance, get approved for free medication, then switch to compounded tirzepatide because "the vial method gives me more control over dosing." Free is cheaper than $179. If the pen delivery method works for you, there's no financial reason to switch.

Scenario 3: You're in a clinical trial with free tirzepatide. Patients sometimes drop out of trials to switch to compounded tirzepatide for convenience. You're trading free medication and free medical monitoring for a $179 to $279 monthly cost. Unless the trial visit schedule is genuinely incompatible with your work or family obligations, staying enrolled is the better financial decision.

Scenario 4: Your insurance covers Wegovy but not Zepbound. Wegovy (semaglutide) and Zepbound (tirzepatide) are both GLP-1 receptor agonists for weight management. If your plan covers Wegovy with a $50 copay and excludes Zepbound, taking the covered Wegovy is cheaper than paying $399 to $549 for Zepbound through LillyDirect. Tirzepatide shows superior weight loss in trials, but the difference (6% additional total body weight loss on average) may not justify paying $349 to $499 more per month out of pocket.

Scenario 5: You're considering international pharmacies to save $300/month. The counterfeit risk and importation legal ambiguity are not worth $300 monthly savings when compounded tirzepatide from a U.S.-licensed pharmacy costs $179 to $350. You're taking on regulatory risk and product authenticity risk to save $0 to $150 per month. The risk-adjusted value is negative.

The correct cost-reduction strategy is the one that minimizes your cost without increasing clinical risk, legal risk, or administrative burden disproportionately.

FormBlends clinical pattern: what we see in cost-driven treatment gaps

Across FormBlends's patient population initiating compounded tirzepatide between January 2024 and March 2026, we see a consistent pattern in insurance-to-compounded transitions.

The typical patient who switches from attempting brand-name Zepbound to compounded tirzepatide follows this sequence:

Month 1: Provider writes Zepbound prescription. Patient submits to insurance. Insurance requires prior authorization.

Month 2: Prior authorization submitted. Insurance denies, citing step therapy requirement (must try metformin or phentermine first) or BMI threshold not met (plan requires BMI ≥35, patient has BMI 32).

Month 3: Provider appeals denial. Appeal denied. Patient is quoted $1,150 cash price at local pharmacy. Patient searches "how to get Zepbound cheap" and discovers compounded options.

Month 4: Patient enrolls in telehealth platform, receives compounded tirzepatide prescription, begins treatment at $179 to $279/month.

The three-month delay between initial prescription attempt and treatment start is the cost-driven treatment gap. The patient wanted to start in Month 1. Financial and administrative barriers delayed start to Month 4.

This pattern appears in approximately 60% of our compounded tirzepatide initiations where the patient has commercial insurance. The remaining 40% are uninsured from the start or have government insurance (Medicare/Medicaid) that categorically excludes coverage.

The clinical implication: patients who eventually succeed in accessing affordable tirzepatide lose an average of 90 days of treatment time navigating insurance barriers. For a medication where earlier initiation correlates with better long-term adherence (Wilding et al., Lancet 2024), the delay has downstream effects on outcomes.

The policy implication: if the goal is to increase access to effective obesity pharmacotherapy, reducing the prior authorization and appeal timeline would have more impact than further price reductions. The medication is already accessible at $179 to $279 through compounding. The barrier is information (patients don't know compounding exists) and the three-month insurance navigation period.

FAQ

How much does Zepbound cost without insurance? Zepbound costs $1,060 to $1,350 per month without insurance at retail pharmacies. With discount cards like GoodRx, the price drops to $980 to $1,120. LillyDirect offers $399 to $549 monthly pricing for uninsured patients. Compounded tirzepatide costs $179 to $350 per month.

Does the Lilly savings card work if I don't have insurance? No. The Lilly savings card reduces a copay for patients with commercial insurance. If you have no insurance, there's no copay to reduce, and the card provides no benefit. Uninsured patients should use LillyDirect, patient assistance programs, or compounded tirzepatide instead.

What is the cheapest way to get Zepbound? For patients who qualify, the Lilly Cares Foundation patient assistance program provides free Zepbound (income must be below $60,240/year for individuals). For patients who don't qualify, compounded tirzepatide at $179 to $350/month is the cheapest option.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved, comes in vials rather than pens, and is prepared by compounding pharmacies rather than manufactured by Eli Lilly. It's not interchangeable with Zepbound but provides the same therapeutic effect at lower cost.

Can I use GoodRx for Zepbound? Yes. GoodRx coupons reduce Zepbound's cash price by $100 to $250 per fill. You cannot combine GoodRx with insurance. If you use GoodRx, you're paying cash, and the cost doesn't count toward your insurance deductible.

Does Medicare cover Zepbound? Medicare Part D plans sometimes cover Zepbound for weight management, but coverage varies by plan. Most plans place it on specialty tiers with $200 to $500 copays. Medicare patients cannot use the Lilly savings card. Check your plan's formulary or contact your Part D provider.

How do I apply for Lilly patient assistance? Visit LillyCares.com, complete the patient application, have your provider complete the prescriber section, and submit proof of income (tax return or pay stubs). Approval takes 10 to 15 business days. If approved, Zepbound ships free to your home for up to 12 months.

Is LillyDirect cheaper than retail pharmacies? Yes. LillyDirect charges $399 to $549 per month depending on dose. Retail pharmacies charge $1,060 to $1,350 cash price. LillyDirect saves $461 to $801 monthly but requires using LillyDirect's telehealth providers rather than your existing doctor.

Can I buy Zepbound from Canada? Technically yes, but it's legally ambiguous and carries risks. Canadian pharmacies sell Zepbound at CAD $975 (USD $720). FDA prohibits importation, but enforcement against personal-use quantities is rare. Counterfeit risk and shipping temperature control are concerns. Compounded tirzepatide from U.S. pharmacies is safer and often cheaper.

What if my insurance denies Zepbound? If your insurance denies coverage, ask your provider to submit an appeal with medical necessity documentation (BMI, comorbidities, prior weight loss attempts). If the appeal is denied, consider LillyDirect ($399 to $549/month), patient assistance if income-qualified (free), or compounded tirzepatide ($179 to $350/month).

How long does the Lilly savings card last? The Lilly Zepbound Savings Card is valid for up to 13 fills (approximately one year of treatment). After 13 fills, you pay your plan's regular copay unless Lilly extends the program. Check the card's terms annually for updates.

Is Zepbound covered by Medicaid? Coverage varies by state. Some state Medicaid programs cover Zepbound for weight management with prior authorization. Others exclude it entirely. Check your state's Medicaid formulary or contact your managed care plan. Medicaid patients cannot use the Lilly savings card.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Institute for Clinical and Economic Review. Tirzepatide for Weight Management: Effectiveness and Value. ICER. 2024.
4. Eli Lilly and Company. Corporate Responsibility Report 2024. Lilly. 2024.
5. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 trial. Nature Medicine. 2023.
6. National Association of Boards of Pharmacy. Internet Drug Outlet Identification Program Progress Report. NABP. 2023.
7. Wilding JPH et al. Long-term efficacy and safety of tirzepatide in patients with obesity. Lancet. 2024.
8. U.S. Food and Drug Administration. Zepbound Prescribing Information. FDA. 2023.
9. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File 2026. CMS. 2026.
10. Canadian Patented Medicine Prices Review Board. Annual Report 2024. PMPRB. 2024.
11. GoodRx Research Team. GLP-1 Medication Pricing Analysis Q1 2026. GoodRx. 2026.
12. Lilly Cares Foundation. Patient Assistance Program Guidelines 2026. Lilly Cares. 2026.
13. American Medical Association. Prior Authorization Physician Survey 2024. AMA. 2024.
14. Academy of Managed Care Pharmacy. Specialty Medication Trends Report 2025. AMCP. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers. Walmart, CVS, Walgreens, Costco, Sam's Club, GoodRx, and LillyDirect are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.